|
CORE CORPORATE STRATEGY SERVICES
● Corporate and technology positioning
for funding and/or acquisitions
● Structuring and negotiation of
partnerships and alliances
● Market analysis
● Technology evaluation and due
diligence
● Business plan development/review
● Product management and support
● Patent research and analysis
● Brand and corporate communications
● Bioprocess and manufacturing
PROVEN RESULTS
● Developed strategies that have raised
over $120 million USD in corporate financing
● Repositioned company in antibody space
leading to series B and a $500 million USD
partnership
deal
● Closed over 35 partnership deals for
clients
● Developed/executed 3 year strategy to
take early company to profitability
● Marketing strategy that led to $12
Million in private financing
● Developed business strategy for an
emerging translational medicine institute
● Developed IP strategy to allow client
a license-free development program in the
monoclonal
antibody space

BIOPROCESSING AND MANUFACTURING SERVICES
● Bioprocess troubleshooting and process
development guidance
● Technology, facilities and equipment
evaluation
● Due diligence for development programs
● Due diligence for process and
manufacturing related IP
● Contract vendor arrangements and
management
● Management of process/technology
transfer and its implementation
● Project management: CMC and Drug
Development
● CMC regulatory submission preparation
and review
● Corporate and technology positioning
EXPERTISE
● Process development utilizing
mammalian, E. coli and yeast hosts
● Manufacturing strategies
● Expression technologies and cell line
development strategies
● Downstream process development
● Biopharmaceuticals manufacturing, pre
IND through commercial
● Facilities layout, design and
evaluation
● Broad range of experience with
biologics development, including monoclonal antibodies,
growth
factors, cytokines and the clotting cascade

CORPORATE FACT SHEETS
 |
|



 |
"DNA Bridges was very good at bringing in other experts.
They were instrumental in getting the opinions of important
people about this project and doing the necessary
preliminary PR."
|
 |
|
- Project leader at biotech start-up.
An independent third party conducted a quality
survey for DNA Bridges,Inc. The third party, in association with
Dunn and Bradstreet, interviewed several clients. All
clients stated that the costs met expectations and projects
were competed on time.
|
|